Hemostatic changes in patients with liver cirrhosis

Chinese Medical Journal (Taipei)

Volumn 62, Issue 6, 1999, Pages 376-382

  Ho, Chao Hung ^a,b   Hou, Ming Chih ^a,b   Lin, Han Chieh ^a,b   Lee, Fa Yauh ^a,b   Wu, Jaw Ching ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Child Pugh classification; Hemostatic change; Liver cirrhosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME;

EID: 0033042840     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mannucci PM, Giangrande PLF. Acquired disorders of coagulation. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. London: Churchill Livingstone, 1994:949-68.
2. Ratnoff OD. Hemostatic defects in liver and biliary tract disease and disorders of vitamin K metabolism. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. New York: Grune and Stratton, 1984:451-72.
3. Flute PT. Acquired disorders of blood coagulation. In: Hardisty RM, Weatherall DJ, eds. Blood and its Disorders. Melbourne: Blackwell Scientific Publications, 1982; 1161-89.
4. Bloom A. Intravascular coagulation in the liver. Br J Haematol 1975;30:1-7.
5. DeCaterina M, Tarantino G, Farina C, Arena A, DiMaro G, Esposito P, Scopacasa F. Haemostasis unbalance in Pughscored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S. Haemostasis 1993;23: 229-35.
6. Vukovich T, Teufelsbauer H, Fritzer M, Kreuzer S, Knoflach P. Hemostasis activation in patients with, liver cirrhosis. Thromb Res 1995;77:271-S.
7. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 1993;17:78-83.
8. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. Hepatology 1995;22:96-100.
9. Violi F, Leo R, Vezza E, Basili S, Cordova D, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. CALC Group. J Hepatol 1994;20:531-6.
10. Pugh RNH, Marray-Lyon M, Dawson JL, Pietroni MC, Williams R. Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
11. Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981;1:673-6.
12. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17:37-246.
13. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (tPA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to tPA. Thromb Hemostas 1985;54: 684-7.
14. Declerck PJ, Alessim C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-5.
15. Chakrabarti M, Bielawiec JF, Evans JF, Feamley GR. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Pathol 1968;21: 698-701.
16. Nilsson IM, Robertson B. Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thromb Diathes Haemorrhag 1968;20:397-408.
17. Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975;6: 287-95.
18. Silverstein RM. The determination of human plasminogen using N (A) CBZ-L. Lysine-Paranitrophenyl ester as substrate. Anal Biochem 1975;65:500-6.
19. Amiral J. Evaluation of ATM (modified ATIII) - a marker of blood activation. In: Thrombotic and Prethrombotic Markers - Abstract from 6th International Symposium. Paris: Diagnostica Stago, 1990:21-5.
20. Latallo ZS, Wegrzynowicz Z, Teisseyre E, Kopec M. Simple and rapid evaluation of the intravascular coagulation and fibrinolytic states by application of protamine sulphate and reptilase R. Scand J Haematol 1971;13:387-8.
21. Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994;14:769-80.
22. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992;6:1247-57.
23. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994;78:545-54.
24. Kelly DA, Summerfield JA. Hemostasis in liver disease. Semin Liver Dis 1987;7:182-91.
25. Knot EA, TenCate FW, Dnjfhout HR, Kahle LH, Tytgat GN. Antithrombin in metabolism in patients with liver disease. J Clin Pathol 1984;37:523-30.
26. Bithell TC. Blood coagulation. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's Clinical Hematology. Philadelphia: Lea and Febiger, 1993:566-615.
27. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992;15:672-6.
28. Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter JR, Bachmann F, Kruithoff EKO. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemostas 1989;62:651-3.
29. Lasierra J, Aza MJ, Vilades E, Poblet S, Barrao F, Bayon E, Gonzales J. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis. Fibrinolysis 1991;5:117-20.